Yet, despite the five EGFR-TKIs (gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib) currently available for the treatment of EGFRM+ NSCLC, the ideal sequence for administering these drugs remains to be established [294]. Here, EGFR is linked to non-small cell lung carcinoma.